Coralville, IA – According to filings with the U.S. Securities and Exchange Commission, Viewpoint Molecular Targeting is raising $15,847,498.00 in new funding. Sources indicate as part of senior management Chief Medical Officer, Frances Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

To learn more about Viewpoint Molecular Targeting, visit http://viewpointmt.com/

Contact:
Frances Johnson, Chief Medical Officer
865-356-1861
https://www.linkedin.com/in/francesjohnson1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved